Biotech sector is having a generational moment in Canada

Fresh off a vitriolic activist battle that spurred the ouster of three board members, Exelixis plans to hydrate its pipeline with artificial intelligence. The company, known for solid tumor med Cabometyx, is licensing a phase 1 small molecule from Insilico Medicine for $80 million in addition to undisclosed milestone payments, according to Tuesday announcement. The deal gives Exelixis worldwide ri